Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01777984Unknown

Impact of Visceral Fat on the Pathogenesis of Age-related Macular Degeneration

Role: lead

NCT01174407Unknown

Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration

Role: lead

NCT00532142Phase 2Completed

The ROVO Study: Radial Optic Neurotomy for CVO

Role: lead

NCT00569569Phase 2Completed

Retaane® in Age-Related Macular Degeneration

Role: lead

NCT00533754Not ApplicableUnknown

Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population

Role: lead

All 5 trials loaded